Old and new synthetic cannabinoids: lessons from animal models

Drug Metabolism Reviews

Volumn 50, Issue 1, 2018, Pages 54-64

  Zanda, Mary Tresa ^a   Fattore, Liana ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

Author keywords

abuse liability; animal models; conditioned place preference; drug discrimination; reward; self administration; Synthetic cannabinoids

Indexed keywords

CANNABINOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONDITIONED PLACE PREFERENCE TEST; DRUG DEPENDENCE; DRUG DISCRIMINATION TEST; DRUG SELF ADMINISTRATION; HUMAN; NONHUMAN; REVIEW; REWARD; ANIMAL; CANNABIS ADDICTION; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; INSTRUMENTAL CONDITIONING;

ANIMALS; CANNABINOIDS; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; MARIJUANA ABUSE; MODELS, ANIMAL; SELF ADMINISTRATION;

EID: 85043573921     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/03602532.2018.1430824     Document Type: Review

References (104)

1. Amchova P, Kucerova J, Giugliano V, Babinska Z, Zanda MT, Scherma M, Dusek L, Fadda P, Micale V, Sulcova A, et al. 2014. Enhanced self-administration of the CB1 receptor agonist WIN55,212-2 in olfactory bulbectomized rats: evaluation of possible serotonergic and dopaminergic underlying mechanisms. Front Pharmacol. 5:44.
2. Aston-Jones G, Harris GC., 2004. Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology. 47:167–179.
3. Bardo MT, Bevins RA., 2000. Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology (Berl). 153:31–43.
4. Beardsley PM, Dance ME, Balster RL, Munzar P., 2002. Evaluation of the reinforcing effects of the cannabinoid CB1 receptor antagonist, SR141716, in rhesus monkeys. Eur J Pharmacol. 435:209–216.
5. Botanas CJ, de la Peña JB, Dela Pena IJ, Tampus R, Kim HJ, Yoon SS, Seo JW, Jeong EJ, Cheong JH., 2015. Evaluation of the abuse potential of AM281, a new synthetic cannabinoid CB1 receptor antagonist. Eur J Pharmacol. 766:135–141.
6. Braida D, Pozzi M, Cavallini R, Sala M., 2001. Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system. Neuroscience. 104:923–926.
7. Braida D, Pozzi M, Parolaro D, Sala M., 2001. Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. Eur J Pharmacol. 413:227–234.
8. Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE., 2013. Differential drug–drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. J Pharmacol Exp Ther. 346:350–361.
9. Bush DM, Woodwell DA., 2014. Update: drug-related emergency department visits involving synthetic cannabinoids. The CBHSQ report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US).
10. Canazza I, Ossato A, Trapella C, Fantinati A, De Luca MA, Margiani G, Vincenzi F, Rimondo C, Di Rosa F, Gregori A, et al. 2016. Effect of the novel synthetic cannabinoids AKB48 and 5F-AKB48 on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. In vitro and in vivo pharmacological studies. Psychopharmacology (Berl). 233:3685–3709.
11. Carvalho AF, Reyes BA, Ramalhosa F, Sousa N, Van Bockstaele EJ., 2016. Repeated administration of a synthetic cannabinoid receptor agonist differentially affects cortical and accumbal neuronal morphology in adolescent and adult rats. Brain Struct Funct. 221:407–419.
12. Cha HJ, Lee KW, Song MJ, Hyeon YJ, Hwang JY, Jang CG, Ahn JI, Jeon SH, Kim HU, Kim YH, et al. 2014. Dependence potential of the synthetic cannabinoids JWH-073, JWH-081, and JWH-210: in vivo and in vitro approaches. Biomol Ther (Seoul). 22:363–369.
13. Chaperon F, Soubrié P, Puech AJ, Thiébot MH., 1998. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl). 135:324–332.
14. Cheer JF, Kendall DA, Marsden CA., 2000. Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology (Berl). 151:25–30.
15. Christie G, MacFarlane V., 2016. Synthetic cannabinoid presentations decline following ban. Drug Alcohol Rev. 35:E3–E4.
16. De Luca MA, Bimpisidis Z, Melis M, Marti M, Caboni P, Valentini V, Margiani G, Pintori N, Polis I, Marsicano G, et al. 2015. Stimulation of in vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a spice cannabinoid. Neuropharmacology. 99:705–714.
17. De Luca MA, Fattore L., 2018. Therapeutic use of synthetic cannabinoids: still an open issue? Clin Ther. in press.
18. Deiana S, Fattore L, Spano MS, Cossu G, Porcu E, Fadda P, Fratta W., 2007. Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology. 52:646–654.
19. [DEA] Drug Enforcement Administration, Department of Justice. 2017. Schedules of controlled substances: temporary placement of FUB–AMB into schedule I. Temporary amendment; temporary scheduling order. Fed Reg. 82:51154–51158.
20. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2013. Perspectives on drugs: synthetic cannabinoids in Europe. Luxembourg: Publications Office of the European Union.
21. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 2017. European drug report 2017: trends and developments. Luxembourg: Publications Office of the European Union.
22. Fadda P, Scherma M, Spano MS, Salis P, Melis V, Fattore L, Fratta W., 2006. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport. 17:1629–1632.
23. Fattore L, Cossu G, Martellotta CM, Fratta W., 2001. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology (Berl). 156:410–416.
24. Fattore L, Diana M., 2016. Drug addiction: an affective-cognitive disorder in need of a cure. Neurosci Biobehav Rev. 65:341–361.
25. Fattore L, Fadda P, Fratta W., 2007. Endocannabinoid regulation of relapse mechanisms. Pharmacol Res. 56:418–427.
26. Fattore L, Fadda P, Fratta W., 2009. Sex differences in the self-administration of cannabinoids and other drugs of abuse. Psychoneuroendocrinology. 34:S227–S236.
27. Fattore L, Fratta W., 2011. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci. 5:60.
28. Fattore L, Martellotta MC, Cossu G, Mascia MS, Fratta W., 1999. CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. Behav Brain Res. 104:141–146.
29. Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W., 2007. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br J Pharmacol. 152:795–804.
30. Fattore L, Spano MS, Altea S, Fadda P, Fratta W., 2010. Drug- and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: influence of ovarian hormones. Br J Pharmacol. 160:724–735.
31. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W., 2003. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci. 17:1723–1726.
32. Fattore L, Spano S, Cossu G, Deiana S, Fadda P, Fratta W., 2005. Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology. 48:1097–1104.
33. Fattore L, Viganò D, Fadda P, Rubino T, Fratta W, Parolaro D., 2007. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci. 25:2191–2200.
34. Fattore L., 2016. Synthetic cannabinoids—further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry. 79:539–548.
35. Gardner EL., 2011. Addiction and brain reward and antireward pathways. Adv Psychosom Med. 30:22–60.
36. Gatch MB, Forster MJ., 2014. Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/spice. Behav Pharmacol. 25:750–757.
37. Gatch MB, Forster MJ., 2015. Δ9-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids found on the gray market. Behav Pharmacol. 26:460–468.
38. Gatch MB, Forster MJ., 2016. Δ(9)-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice and rats. Psychopharmacology (Berl). 233:1901–1910.
39. Gatch MB, Forster MJ., 2017. Δ(9)-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats. Psychopharmacology (Berl). doi:10.1007/s00213-017-4783-6.
40. 9-tetrahydrocannabinol-like discriminative stimulus effects in monkeys. J Pharmacol Exp Ther. 340:37–45.
41. Glue P, Courts J, Gray A, Patterson T., 2016. Influence of law changes affecting synthetic cannabinoid availability and frequency of hospital presentations: 4-year national survey. N Z Med J. 129:37–40.
42. Gold LH, Balster RL, Barrett RL, Britt DT, Martin BR., 1992. A comparison of the discriminative stimulus properties of A′-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. J Pharm Exp Ther. 262:479–486.
43. Grim TW, Samano KL, Ignatowska-Jankowska B, Tao Q, Sim-Selly LJ, Selley DE, Wise LE, Poklis A, Lichtman AH., 2016. Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497. J Basic Clin Physiol Pharmacol. 27:217–228.
44. Hruba L, McMahon LR., 2014. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys. Eur J Pharmacol. 727:35–42.
45. Hyatt WS, Fantegrossi WE., 2014. Δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice. Behav Pharmacol. 25:253–257.
46. Järbe TU, Deng H, Vadivel SK, Makriyannis A., 2011. Cannabinergic aminoalkylindoles, including AM678 = JWH018 found in ‘Spice’, examined using drug (Delta9-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol. 22:498–507.
47. Järbe TU, Gifford RS, Zvonok A, Makriyannis A., 2016. Δ9-Tetrahydrocannabinol discriminative stimulus effects of AM2201 and related aminoalkylindole analogs in rats. Behav Pharmacol. 27:211–214.
48. Järbe TU, Gifford RS., 2014. “Herbal incense”: designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays. Life Sci. 97:64–71.
49. Järbe TU, Li C, Vadivel SK, Makriyannis A., 2010. Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol. Psychopharmacology (Berl). 208:87–98.
50. Järbe TU, Mathis DA., 1991. Discriminative stimulus functions of cannabinoids/cannabimimetics. NIDA Res Monogr. 116:75–99.
51. John WS, Martin TJ, Nader MA., 2017. Behavioral determinants of cannabinoid self-administration in old world monkeys. Neuropsychopharmacology. 42:1522–1530.
52. Justinova Z, Goldberg SR, Heishman SJ, Tanda G., 2005. Self-administration of cannabinoids by experimental animals and human marijuana smokers. Pharmacol Biochem Behav. 81:285–299.
53. Justinova Z, Tanda G, Redhi GH, Goldberg SR., 2003. Self-administration of Delta(9)-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl). 169:135–140.
54. Kamien JB, Bickel WK, Hughes JR, Higgins ST, Smith BJ., 1993. Drug discrimination by humans compared to nonhumans: current status and future directions. Psychopharmacology (Berl). 111:259–270.
55. Kirschmann EK, Pollock MW, Nagarajan V, Torregrossa MM., 2017. Effects of adolescent cannabinoid self-administration in rats on addiction-related behaviors and working memory. Neuropsychopharmacology. 42:989–1000.
56. Koek W., 2011. Drug-induced state-dependent learning: review of an operant procedure in rats. Behav Pharmacol. 22:430–440.
57. Lepore M, Vorel SR, Lowinson J, Gardner EL., 1995. Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci. 56:2073–2080.
58. Liu T, Zheng Q, Qian Z, Wang H, Liu Z, Ren W, Zhang X, Han J., 2016. Cannabinoid-elicited conditioned place preference in a modified behavioral paradigm. Biol Pharm Bull. 39:747–753.
59. Liu Y, Le Foll B, Liu Y, Wang X, Lu L., 2008. Conditioned place preference induced by licit drugs: establishment, extinction, and reinstatement. Sci World J. 8:1228–1245.
60. López-Moreno JA, González-Cuevas G, Rodríguez de Fonseca F, Navarro M., 2004. Long-lasting increase of alcohol relapse by the cannabinoid receptor agonist WIN 55,212-2 during alcohol deprivation. J Neurosci. 24:8245–8252.
61. Lynch WJ, Nicholson KL, Dance ME, Morgan RW, Foley PL., 2010. Animal models of substance abuse and addiction: implications for science, animal welfare, and society. Comp Med. 60:177–188.
62. Maldonado R., 2002. Study of cannabinoid dependence in animals. Pharmacol Ther. 95:153–164.
63. Mansbach RS, Nicholson KL, Martin BR, Balster RL., 1994. Failure of Delta(9)-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys. Behav Pharmacol. 5:219–225.
64. Marshell R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, Fantegrossi WE., 2014. In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection. Pharmacol Biochem Behav. 124:40–47.
65. Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W., 1998. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience. 85:327–330.
66. Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, Roques BP, Noble F., 2001. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol. 132:1809–1816.
67. McGregor IS, Issakidis CN, Prior G., 1996. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacol Biochem Behav. 53:657–664.
68. Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA., 2016. Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front Neurosci. 10:153.
69. Müller CP., 2017. Animal models of psychoactive drug use and addiction–present problems and future needs for translational approaches. Behav Brain Res. doi: 10.1016/j.bbr.2017.06.028.
70. Nader MA, Tatham TA, Barrett JE., 1982. Behavioral and pharmacological determinants of drug abuse. Ann NY Acad Sci. 654:368–385.
71. Ossato A, Canazza I, Trapella C, Vincenzi F, De Luca MA, Rimondo C, Varani K, Borea PA, Serpelloni G, Marti M., 2016. Effect of JWH-250, JWH-073 and their interaction on “tetrad”, sensorimotor, neurological and neurochemical responses in mice. Prog Neuropsychopharmacol Biol Psychiatry. 67:31–50.
72. Ossato A, Uccelli L, Bilel S, Canazza I, Di Domenico G, Pasquali M, Pupillo G, De Luca MA, Boschi A, Vincenzi F, et al. 2017. Psychostimulant effect of the synthetic cannabinoid JWH-018 and AKB48: behavioral, neurochemical, and dopamine transporter scan imaging studies in mice. Front Psychiatry. 8:130.
73. Panlilio LV, Goldberg SR., 2007. Self-administration of drugs in animals and humans as a model and an investigative tool. Addiction. 102:1863–1870.
74. Panlilio LV, Justinova Z, Goldberg SR., 2010. Animal models of cannabinoid reward. Br J Pharmacol. 160:499–510.
75. Parker LA, Gillies T., 1995. THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav Neurosci. 109:71–78.
76. Planeta CS., 2013. Animal models of alcohol and drug dependence. Rev Bras Psiquiatr. 35:S140–S146.
77. Prus AJ, James JR, Rosecrans JA., 2009. Chapter 4: conditioned place preference. In: Buccafusco JJ, editor. Methods of behavior analysis in neuroscience. 2nd ed. Boca Raton (FL): CRC Press/Taylor & Francis.
78. Rodriguez JS, McMahon LR., 2014. JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects. Eur J Pharmacol. 740:151–159.
79. Sanchis-Segura C, Spanagel R., 2006. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol. 11:2–38.
80. Scherma M, Dessì C, Muntoni AL, Lecca S, Satta V, Luchicchi A, Pistis M, Panlilio LV, Fattore L, Goldberg SR, et al. 2016. Adolescent Δ(9)-tetrahydrocannabinol exposure alters WIN55,212-2 self-administration in adult rats. Neuropsychopharmacology. 41:1416–1426.
81. Seely KA, Lapoint J, Moran JH, Fattore L., 2012. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 39:234–243.
82. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J., 2003. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl). 168:3–20.
83. Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR., 2006. Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc. 1:1194–1206.
84. Solinas M, Scherma M, Fattore L, Stroik J, Wertheim C, Tanda G, Fratta W, Goldberg SR., 2007. Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. J Neurosci. 27:5615–5620.
85. Spano MS, Fadda P, Frau R, Fattore L, Fratta W., 2010. Cannabinoid self-administration attenuates PCP-induced schizophrenia-like symptoms in adult rats. Eur Neuropsychopharmacol. 20:25–36.
86. Spano MS, Fattore L, Cadeddu F, Fratta W, Fadda P., 2013. Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats. Psychopharmacology (Berl). 225:531–542.
87. Spano MS, Fattore L, Cossu G, Deiana S, Fadda P, Fratta W., 2004. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Br J Pharmacol. 143:343–350.
88. Stolerman IP, Childs E, Ford MM, Grant KA., 2011. Role of training dose in drug discrimination: a review. Behav Pharmacol. 22:415–429.
89. Struik D, Fadda P, Zara T, Zamberletti E, Rubino T, Parolaro D, Fratta W, Fattore L., 2017. The anabolic steroid nandrolone alters cannabinoid self-administration and brain CB1 receptor density and function. Pharmacol Res. 115:209–217.
90. Tampus R, Yoon SS, de la Peña JB, Botanas CJ, Kim HJ, Seo JW, Jeong EJ, Jang CG, Cheong JH., 2015. Assessment of the abuse liability of synthetic cannabinoid agonists JWH-030, JWH-175, and JWH-176. Biomol Ther (Seoul). 23:590–596.
91. Tanda G, Munzar P, Goldberg SR., 2000. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci. 3:1073–1074.
92. Thomsen M, Caine SB., 2005. Chronic intravenous drug self-administration in rats and mice. Curr Protoc Neurosci. Chapter 9:Unit 9.20. doi: 10.1002/0471142301.ns0920s32.
93. Tzschentke TM., 1998. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol. 56:613–672.
94. Tzschentke TM., 2007. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol. 12:227–462.
95. United Nations Office on Drugs and Crime (UNODC). 2017. World drug report 2017 (United Nations publication, Sales No. E.17.XI.6).
96. Vanderschuren LJ, Ahmed SH., 2013. Animal studies of addictive behavior. Cold Spring Harb Perspect Med. 3:a011932.
97. Venniro M, Caprioli D, Shaham Y., 2016. Animal models of drug relapse and craving: from drug priming-induced reinstatement to incubation of craving after voluntary abstinence. Prog Brain Res. 224:25–52.
98. 9-tetrahydrocannabinol (THC) self-administration in male and female Long-Evans rats. Exp Clin Psychopharmacol. 25:242–248.
99. Weinstein AM, Rosca P, Fattore L, London ED., 2017. Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front Psychiatry. 8:156.
100. Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR., 1995. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology. 34:669–676.
101. Wiley JL, Lefever TW, Cortes RA, Marusich JA., 2014. Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats. Pharmacol Biochem Behav. 124:123–128.
102. Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, Patel PR, Grabenauer M, Moore KN, Thomas BF., 2015. AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing Δ9-tetrahydrocannabinol-like effects in mice. J Pharmacol Exp Ther. 354:328–339.
103. Wiley JL, Marusich JA, Lefever TW, Grabenauer M, Moore KN, Thomas BF., 2013. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles. Neuropharmacology. 75:145–154.
104. Wise RA, Koob GF., 2014. The development and maintenance of drug addiction. Neuropsychopharmacology. 39:254–262.